Eliquis (Bristol Myers Squibb and Pfizer) is expected to face US generic competition from 2028. US generics barred until 1 April 2028 after patent win and settlements. EU generics earlier. Sales as reported by BMS; Pfizer separately books $8.0B of alliance and product revenue.
Eliquis's US exclusivity date is based on settlement / court date. Litigation settlements or a court ruling fix the earliest US entry date, which makes it one of the firmer dates in this tracker. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Eliquis was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2026, 56% below its list price. That is 2 years before US generics can launch, so Medicare revenue comes under pressure first. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number.
Eliquis is 30% of Bristol Myers Squibb's 2025 revenue ($14.4B of $48.2B). With Pomalyst and Opdivo, the drugs tracked here add up to 56% of Bristol Myers Squibb's revenue losing US exclusivity by 2028.
Eliquis is 13% of Pfizer's 2025 revenue ($8.0B of $62.6B). With Ibrance, Xtandi and Prevnar 20, the drugs tracked here add up to 33% of Pfizer's revenue losing US exclusivity by 2035. Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Eliquis is highlighted.